高级检索
    覃桦, 陈强, 吴英林. 利奈唑胺、替考拉宁及万古霉素治疗ICU内MRSA肺部感染疗效比较[J]. 徐州医科大学学报, 2018, 38(6): 398-402.
    引用本文: 覃桦, 陈强, 吴英林. 利奈唑胺、替考拉宁及万古霉素治疗ICU内MRSA肺部感染疗效比较[J]. 徐州医科大学学报, 2018, 38(6): 398-402.
    shu
    Comparison of the efficacy of the treatment of MRSA pulmonary infection in ICU with linidazolamide, substitute corrine and vancomycin[J]. Journal of Xuzhou Medical University, 2018, 38(6): 398-402.
    Citation: Comparison of the efficacy of the treatment of MRSA pulmonary infection in ICU with linidazolamide, substitute corrine and vancomycin[J]. Journal of Xuzhou Medical University, 2018, 38(6): 398-402.
    shu

    利奈唑胺、替考拉宁及万古霉素治疗ICU内MRSA肺部感染疗效比较

    Comparison of the efficacy of the treatment of MRSA pulmonary infection in ICU with linidazolamide, substitute corrine and vancomycin

      摘要
    • 摘要: 目的：比较利奈唑胺、替考拉宁及万古霉素治疗ICU内耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染疗效。方法：研究对象选取我院ICU2015年10月到2017年2月间收治的MRSA肺部感染患者165例，采用随机数字法将其分为A组、B组及C组，每组各45例，分别给予利奈唑胺、替考拉宁及万古霉素治疗。比较三组患者的治疗总有效率、细菌清除有效率及不良反应发生率，同时比较治疗前后的血清白细胞计数(WBC)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)及C反应蛋白(CRP)水平。结果：A组患者的治疗总有效率和细菌清除率均明显高于B组和C组(P<0.05)，B组和C组比较无明显差异(P>0.05)；治疗后，A组患者的WBC和血清TNF-α、PCT及CRP水平均明显低于B组和C组(P<0.01)，但B组和C组以上指标比较均无明显差异(P>0.05)；三组患者的不良反应发生率比较无明显差异(P>0.05)。结论：利奈唑胺治疗ICU内MRSA肺部感染疗效优于替考拉宁和万古霉素，对MRSA清除更为彻底，且对肺部炎症反应控制效果更佳，同时不良反应发生率相当，临床可优先选择利奈唑胺治疗。

       

      Abstract: Objective:To compare the efficacy of the treatment of the pulmonary infection of MRSA in ICU in the treatment of ICU.Methods:The subjects were 165 patients with MRSA pulmonary infection received from ICU between 2015 October 2015 to February 2017,randomly divided them into group A, group B and group C, 45 cases each group ,respectively treated with the treatment of linazolamide,teicoplanin and vancomycin. Comparison of three groups of patients with total effective rate, bacterial removal efficient and incidence of adverse reactions, and compared before and after treatment serum white blood cell count (WBC), tumor necrosis factor alpha (TNF alpha), calcitonin (PCT) and c-reactive protein (CRP) level. Results: The total effective rate of treatment and bacterial clearance in group A were significantly higher than those in group B and C(P<0.05), and there was no significant difference between group B and group C (P>0.05);After treatment, the levels of WBC and serum TNF- alpha, PCT and CRP in group A were significantly lower than those in group B and C (P<0.01), but there was no significant difference between group B and group C (P<0.05). There was no significant difference in adverse reactions between the three groups(P<0.05).Conclusion:Linazolamide treatment in ICU pulmonary infection of MRSA curative effect is better than that of their teicoplanin and vancomycin, cleared to MRSA more thoroughly, the lung inflammatory response and control effect is better, and incidence of adverse reactions, clinical can give preference to rina thiazole amine treatment

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回